Drugs / QN-019a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05379647 | Nov 2021 → Jun 2024 | B-cell acute lymphoblastic leukemia | Zhejiang University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-07-17 | Hangzhou Qihan Biotech Co., Ltd. | Regulatory Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma qihanbio.com ↗
According to the official website of the Center for Drug Evaluation, NMPA, the clinical trial application for QN-019a cell injection has received approval as of July 18, 2023. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-07-17 | Hangzhou Qihan Biotech Co., Ltd. | Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma qihanbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QN-019a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05379647 ↗ |
| Modality | Cell therapy | “allogeneic CAR-NK cells targeting CD19” NCT05379647 ↗ |
| Target | CD19 | “targeting CD19” NCT05379647 ↗ |